Reply to T.L. Ng et al and L. Celio et al
Authors:
- 10 July 2014
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (20) , 2187-2188
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron?Journal of Clinical Oncology, 2014
- Aprepitant Versus Dexamethasone to Prevent Delayed Emesis After ChemotherapyJournal of Clinical Oncology, 2014
- Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind StudyJournal of Clinical Oncology, 2014
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupportive Care in Cancer, 2010
- Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapyAnnals of Oncology, 2010
- Statistical considerations in the design, conduct and analyses of antiemetic clinical trialsSupportive Care in Cancer, 1998
- On the relationship between nausea and vomiting in patients undergoing chemotherapySupportive Care in Cancer, 1994